Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 ...

Recursion Pharmaceuticals recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and revenue but an ...

Recursion reported $83 million in pro forma revenue for 2024, with key contributions from partnerships and milestone payments. The company ended 2024 with over $600 million in cash, ensuring ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 ...

QID and Q6H are both medical abbreviations used on prescription medications. QID medications should be taken four times a day, while Q6H should be taken every six hours. While this may seem redundant, ...